Is SGHT or LNSR more profitable?

LENSAR has a net margin of 50.94% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -46.83% -52.34% -28.49% LENSAR 50.94% -183.19% 42.26%

Which has better valuation and earnings, PROF or LNSR?

LENSAR has higher revenue and earnings than Profound Medical. LENSAR is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profound Medical $16.10M 14.83 -$42.57M -$1.24 N/A LENSAR $58.44M 1.16 -$34.28M -$0.58 N/A

Is PROF or LNSR more profitable?

LENSAR has a net margin of 50.94% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets Profound Medical -206.76% -78.88% -64.06% LENSAR 50.94% -183.19% 42.26%

Does the media prefer PROF or LNSR?

In the previous week, LENSAR had 1 more articles in the media than Profound Medical. MarketBeat recorded 2 mentions for LENSAR and 1 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.00 beat LENSAR's score of -0.34 indicating that Profound Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profound Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to TMCI or LNSR?

In the previous week, LENSAR had 1 more articles in the media than Treace Medical Concepts. MarketBeat recorded 2 mentions for LENSAR and 1 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 1.57 beat LENSAR's score of -0.34 indicating that Treace Medical Concepts is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Treace Medical Concepts 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, OBIO or LNSR?

LENSAR has higher revenue and earnings than Orchestra BioMed. LENSAR is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $33.48M 7.06 -$52.70M -$0.97 N/A LENSAR $58.44M 1.16 -$34.28M -$0.58 N/A

Is OBIO or LNSR more profitable?

LENSAR has a net margin of 50.94% compared to Orchestra BioMed's net margin of -166.96%. Orchestra BioMed's return on equity of -157.46% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -166.96% -157.46% -60.18% LENSAR 50.94% -183.19% 42.26%

Does the media prefer OBIO or LNSR?

In the previous week, Orchestra BioMed had 3 more articles in the media than LENSAR. MarketBeat recorded 5 mentions for Orchestra BioMed and 2 mentions for LENSAR. Orchestra BioMed's average media sentiment score of 0.16 beat LENSAR's score of -0.34 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, RXST or LNSR?

LENSAR has lower revenue, but higher earnings than RxSight. LENSAR is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $127.48M 1.61 -$38.94M -$1.13 N/A LENSAR $58.44M 1.16 -$34.28M -$0.58 N/A

Is RXST or LNSR more profitable?

LENSAR has a net margin of 50.94% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% LENSAR 50.94% -183.19% 42.26%

LENSAR (LNSR) Competitors

$5.60 0.00 (0.00%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$5.56 -0.03 (-0.62%)

As of 06/8/2026 04:10 PM Eastern

Compare

LNSR vs. SGHT, PROF, TMCI, OBIO, and RXST

Should you buy LENSAR stock or one of its competitors? MarketBeat compares LENSAR with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LENSAR include Sight Sciences (SGHT), Profound Medical (PROF), Treace Medical Concepts (TMCI), Orchestra BioMed (OBIO), and RxSight (RXST). These companies are all part of the "medical equipment" industry.

How does LENSAR compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Sight Sciences currently has a consensus price target of $8.14, indicating a potential upside of 75.89%. LENSAR has a consensus price target of $10.00, indicating a potential upside of 78.57%. Given LENSAR's higher possible upside, analysts plainly believe LENSAR is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

LENSAR has a net margin of 50.94% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
LENSAR	50.94%	-183.19%	42.26%

In the previous week, LENSAR had 2 more articles in the media than Sight Sciences. MarketBeat recorded 2 mentions for LENSAR and 0 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 0.00 beat LENSAR's score of -0.34 indicating that Sight Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Sight Sciences	Neutral
LENSAR	Neutral

Sight Sciences has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market. Comparatively, LENSAR has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

LENSAR has lower revenue, but higher earnings than Sight Sciences. LENSAR is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$79.55M	3.17	-$38.43M	-$0.71	N/A
LENSAR	$58.44M	1.16	-$34.28M	-$0.58	N/A

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by company insiders. Comparatively, 66.0% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sight Sciences beats LENSAR on 9 of the 16 factors compared between the two stocks.

How does LENSAR compare to Profound Medical?

Profound Medical (NASDAQ:PROF) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

LENSAR has a net margin of 50.94% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-206.76%	-78.88%	-64.06%
LENSAR	50.94%	-183.19%	42.26%

Profound Medical currently has a consensus target price of $12.00, indicating a potential upside of 82.65%. LENSAR has a consensus target price of $10.00, indicating a potential upside of 78.57%. Given Profound Medical's higher possible upside, research analysts plainly believe Profound Medical is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 1.5% of Profound Medical shares are held by company insiders. Comparatively, 66.0% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, LENSAR had 1 more articles in the media than Profound Medical. MarketBeat recorded 2 mentions for LENSAR and 1 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.00 beat LENSAR's score of -0.34 indicating that Profound Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LENSAR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

LENSAR has higher revenue and earnings than Profound Medical. LENSAR is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	14.83	-$42.57M	-$1.24	N/A
LENSAR	$58.44M	1.16	-$34.28M	-$0.58	N/A

Profound Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Summary

LENSAR beats Profound Medical on 10 of the 16 factors compared between the two stocks.

How does LENSAR compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Treace Medical Concepts currently has a consensus price target of $4.77, suggesting a potential upside of 35.13%. LENSAR has a consensus price target of $10.00, suggesting a potential upside of 78.57%. Given LENSAR's stronger consensus rating and higher possible upside, analysts plainly believe LENSAR is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

LENSAR has a net margin of 50.94% compared to Treace Medical Concepts' net margin of -29.44%. Treace Medical Concepts' return on equity of -67.04% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-29.44%	-67.04%	-30.28%
LENSAR	50.94%	-183.19%	42.26%

In the previous week, LENSAR had 1 more articles in the media than Treace Medical Concepts. MarketBeat recorded 2 mentions for LENSAR and 1 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 1.57 beat LENSAR's score of -0.34 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Treace Medical Concepts	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
LENSAR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by company insiders. Comparatively, 66.0% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LENSAR has lower revenue, but higher earnings than Treace Medical Concepts. LENSAR is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69M	1.08	-$59M	-$0.97	N/A
LENSAR	$58.44M	1.16	-$34.28M	-$0.58	N/A

Treace Medical Concepts has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, LENSAR has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Summary

LENSAR beats Treace Medical Concepts on 10 of the 16 factors compared between the two stocks.

How does LENSAR compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by insiders. Comparatively, 66.0% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

LENSAR has higher revenue and earnings than Orchestra BioMed. LENSAR is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	7.06	-$52.70M	-$0.97	N/A
LENSAR	$58.44M	1.16	-$34.28M	-$0.58	N/A

Orchestra BioMed has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

LENSAR has a net margin of 50.94% compared to Orchestra BioMed's net margin of -166.96%. Orchestra BioMed's return on equity of -157.46% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
LENSAR	50.94%	-183.19%	42.26%

Orchestra BioMed currently has a consensus price target of $13.60, suggesting a potential upside of 244.30%. LENSAR has a consensus price target of $10.00, suggesting a potential upside of 78.57%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Orchestra BioMed had 3 more articles in the media than LENSAR. MarketBeat recorded 5 mentions for Orchestra BioMed and 2 mentions for LENSAR. Orchestra BioMed's average media sentiment score of 0.16 beat LENSAR's score of -0.34 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LENSAR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Orchestra BioMed beats LENSAR on 9 of the 16 factors compared between the two stocks.

How does LENSAR compare to RxSight?

RxSight (NASDAQ:RXST) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

In the previous week, LENSAR had 2 more articles in the media than RxSight. MarketBeat recorded 2 mentions for LENSAR and 0 mentions for RxSight. RxSight's average media sentiment score of 0.00 beat LENSAR's score of -0.34 indicating that RxSight is being referred to more favorably in the media.

Company	Overall Sentiment
RxSight	Neutral
LENSAR	Neutral

LENSAR has lower revenue, but higher earnings than RxSight. LENSAR is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.61	-$38.94M	-$1.13	N/A
LENSAR	$58.44M	1.16	-$34.28M	-$0.58	N/A

LENSAR has a net margin of 50.94% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
LENSAR	50.94%	-183.19%	42.26%

78.8% of RxSight shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 66.0% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

RxSight has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, LENSAR has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

RxSight presently has a consensus target price of $9.44, suggesting a potential upside of 90.80%. LENSAR has a consensus target price of $10.00, suggesting a potential upside of 78.57%. Given RxSight's higher possible upside, research analysts clearly believe RxSight is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

RxSight beats LENSAR on 8 of the 15 factors compared between the two stocks.

Get LENSAR News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNSR vs. The Competition

Export

Metric	LENSAR	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$67.78M	$7.25B	$6.49B	$11.99B
Dividend Yield	N/A	1.19%	2.67%	5.57%
P/E Ratio	-9.66	46.41	23.68	23.74
Price / Sales	1.16	72.51	507.33	108.39
Price / Cash	N/A	25.19	26.99	37.25
Price / Book	-2.57	6.89	10.28	6.78
Net Income	-$34.28M	$159.22M	$3.57B	$337.51M
7 Day Performance	-2.44%	-2.53%	0.28%	-2.34%
1 Month Performance	-0.71%	2.25%	3.27%	1.88%
1 Year Performance	-57.22%	-3.61%	22.22%	25.55%

LENSAR Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNSR LENSAR	1.8581 of 5 stars	$5.60 flat	$10.00 +78.6%	-57.3%	$67.78M	$58.44M	N/A	110
SGHT Sight Sciences	3.6281 of 5 stars	$4.34 -4.4%	$8.14 +87.6%	+10.2%	$247.02M	$79.55M	N/A	210
PROF Profound Medical	1.6401 of 5 stars	$6.48 -2.8%	$12.00 +85.2%	+18.0%	$242.37M	$16.10M	N/A	150
TMCI Treace Medical Concepts	3.301 of 5 stars	$3.47 -3.6%	$4.77 +37.5%	-39.2%	$233.54M	$212.69M	N/A	250	Positive News
OBIO Orchestra BioMed	4.5201 of 5 stars	$3.91 +2.1%	$13.60 +247.8%	+19.3%	$229.34M	$33.48M	N/A	4	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNSR) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LENSAR (LNSR) Competitors

LNSR vs. SGHT, PROF, TMCI, OBIO, and RXST

How does LENSAR compare to Sight Sciences?

Summary

How does LENSAR compare to Profound Medical?

Summary

How does LENSAR compare to Treace Medical Concepts?

Summary

How does LENSAR compare to Orchestra BioMed?

Summary

How does LENSAR compare to RxSight?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR vs. The Competition

LENSAR Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LENSAR (LNSR) Competitors

LNSR vs. SGHT, PROF, TMCI, OBIO, and RXST

How does LENSAR compare to Sight Sciences?

Do analysts recommend SGHT or LNSR?

Is SGHT or LNSR more profitable?

Does the media prefer SGHT or LNSR?

Which has more volatility & risk, SGHT or LNSR?

Which has higher earnings & valuation, SGHT or LNSR?

Do institutionals & insiders have more ownership in SGHT or LNSR?

Summary

How does LENSAR compare to Profound Medical?

Is PROF or LNSR more profitable?

Do analysts prefer PROF or LNSR?

Do insiders and institutionals believe in PROF or LNSR?

Does the media prefer PROF or LNSR?

Which has better valuation and earnings, PROF or LNSR?

Which has more volatility and risk, PROF or LNSR?

Summary

How does LENSAR compare to Treace Medical Concepts?

Do analysts recommend TMCI or LNSR?

Is TMCI or LNSR more profitable?

Does the media refer more to TMCI or LNSR?

Do insiders & institutionals hold more shares of TMCI or LNSR?

Which has higher valuation and earnings, TMCI or LNSR?

Which has more volatility and risk, TMCI or LNSR?

Summary

How does LENSAR compare to Orchestra BioMed?

Do institutionals & insiders have more ownership in OBIO or LNSR?

Which has stronger earnings & valuation, OBIO or LNSR?

Which has more volatility and risk, OBIO or LNSR?

Is OBIO or LNSR more profitable?

Do analysts recommend OBIO or LNSR?

Does the media prefer OBIO or LNSR?

Summary

How does LENSAR compare to RxSight?

Does the media favor RXST or LNSR?

Which has preferable earnings & valuation, RXST or LNSR?

Is RXST or LNSR more profitable?

Do insiders and institutionals believe in RXST or LNSR?

Which has more volatility & risk, RXST or LNSR?

Do analysts recommend RXST or LNSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR vs. The Competition

LENSAR Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools